Sizmaz Selcuk, Esen Ebru, Isik-Ericek Puren, Demircan Nihal
Department of Ophthalmology, Cukurova University School of Medicine, Adana, Turkey.
Clin Exp Optom. 2022 Jan;105(1):55-60. doi: 10.1080/08164622.2021.1896334. Epub 2021 Mar 15.
: Pivotal studies are based on strict treatment regimens of vascular endothelial growth factor blocking drugs in neovascular age-related macular degeneration. However, looser regimens with poorer results have been reported in real-world studies with various outcomes. This results in a search of more precise data to rely on in the management of patients with neovascular age-related macular degeneration.: The aim of this study is to analyse the real-world outcome of vascular endothelial growth factor blocking agents in neovascular age-related macular degeneration.: This is a retrospective comparative study of treatment-naïve patients who received intravitreal aflibercept or ranibizumab administration for neovascular age-related macular degeneration for at least 12 months on an regimen following a loading phase of three-monthly injections. Full eye examination and optical coherence tomography scans were provided at all visits. The drugs were compared on the basis of visual acuity, central macular thickness, and subfoveal choroidal thickness. The baseline optical coherence tomography features were analysed seeking a correlation with the outcome.: One hundred and forty-one eyes were enrolled. The mean age was 71.7 ± 8.5 years. Sixty-eight (48.2%) patients received aflibercept and 73 (51.8%) received ranibizumab injections. The mean number of injections was 6.5 ± 2.5. The mean number of injections were also similar between groups (6.4 ± 2.5 vs. 6.5 ± 2.6, respectively, p = 0.783). At one year, both drugs caused significant increase in visual acuity and decrease in central macular thickness and subfoveal choroidal thickness.: In a real-world setting, aflibercept and ranibizumab yielded similar results at one year in the management of neovascular age-related macular degeneration.
关键研究基于针对新生血管性年龄相关性黄斑变性的血管内皮生长因子阻断药物的严格治疗方案。然而，在具有各种结果的真实世界研究中，已报道了更宽松的治疗方案及较差的结果。这导致人们寻求更精确的数据，以便在新生血管性年龄相关性黄斑变性患者的管理中作为依据。
本研究的目的是分析血管内皮生长因子阻断剂在新生血管性年龄相关性黄斑变性中的真实世界疗效。
这是一项回顾性比较研究，纳入了初治患者，这些患者接受玻璃体内注射阿柏西普或雷珠单抗治疗新生血管性年龄相关性黄斑变性，在三个月一次注射的负荷期后，按照一种方案至少治疗12个月。每次就诊时均进行全眼检查和光学相干断层扫描。根据视力、中心黄斑厚度和黄斑下脉络膜厚度对两种药物进行比较。分析基线光学相干断层扫描特征，以寻找与疗效的相关性。
共纳入141只眼。平均年龄为71.7±8.5岁。68例（48.2%）患者接受阿柏西普治疗，73例（51.8%）患者接受雷珠单抗注射。平均注射次数为6.5±2.5次。两组的平均注射次数也相似（分别为6.4±2.5次和6.5±2.6次，p=0.783）。在1年时，两种药物均使视力显著提高，中心黄斑厚度和黄斑下脉络膜厚度降低。
在真实世界中，阿柏西普和雷珠单抗在治疗新生血管性年龄相关性黄斑变性1年时疗效相似。
